It seems Eisai and Biogen have another hurdle to jump over in their bid to get EU approval for their Alzheimer's disease therapy Leqembi ... or no copy of ApoE4, a form of the gene for the ...

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance ... that is specific to the subcutaneous form. In a statement, Eisai and Biogen said ...

In Utah, patients who consent to "hormonal transgender treatment" or surgery on "sex characteristics" while they are minors ...

The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the monthly intravenous (IV) maintenance regimen of Leqembi ® (lecanemab-irmb ...

Japan’s Eisai and US partner Biogen have announced today update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab (trade name Leqembi) as a treatment for early ...

Susvimo was approved by the FDA in 2021 to treat neovascular age-related macular degeneration (AMD), an advanced form of the disease that can cause rapid and severe vision loss. Susvimo is a ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

When can children or adolescents consent, on their own, for vaccination? What should happen if children and their parents disagree about the desirability of a vaccine? When, if ever, should ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.